Conference on Retroviruses and Opportunistic Infections (Virtual CROI 2021)

Virtual 06 March 2021 - 10 March 2021

Extended duration dapivirine vaginal ring shows promise for HIV prevention

02 Apr 2021 by

The use of a 90-day extended duration vaginal ring containing 100 or 200 mg of the antiretroviral drug dapivirine appeared safe, effective, and acceptable among HIV-negative women, according to results of a phase I trial presented at CROI 2021.

Extended duration dapivirine vaginal ring shows promise for HIV prevention

02 Apr 2021

Hope in sight for an oral antiviral pill against COVID-19

24 Mar 2021 by

The oral antiviral drug molnupiravir, given for 5 days, eliminated SARS-CoV-2 in the nasopharynx of patients with COVID-19, interim results of a phase IIa study have shown, boosting hopes for its potential use in the outpatient setting.

Hope in sight for an oral antiviral pill against COVID-19

24 Mar 2021

Minimal monitoring approach of HCV treatment delivers acceptable SVR

22 Mar 2021 by

A minimal monitoring (MINMON) approach to treatment of hepatitis C virus (HCV) infection with sofosbuvir/velpatasvir appeared to render an acceptable sustained virological response (SVR), according to results of the phase IV ACTG* A5360 trial.

Minimal monitoring approach of HCV treatment delivers acceptable SVR

22 Mar 2021

Intranasal insulin boosts attention, memory in people with HIV

22 Mar 2021 by

Treatment with intranasal insulin (INI) improves the performance of virally suppressed people with HIV (VS-PWH) on neuropsychological tests related to memory and attention, according to a study presented at the virtual Conference on Retroviruses and Opportunistic Infections (CROI) 2021.

Intranasal insulin boosts attention, memory in people with HIV

22 Mar 2021

Inflammation strongly signals CV events in treated female vs male HIV patients

19 Mar 2021 by

For HIV patients treated with antiretroviral therapy (ART), higher levels of inflammatory biomarkers help predict non-AIDS cardiovascular (CV) events more strongly in women than men, according to a study.

Inflammation strongly signals CV events in treated female vs male HIV patients

19 Mar 2021

ART initiation improves long-term depression symptoms in acute HIV

19 Mar 2021 by

Improvements in depression symptoms remain stable at 6 years in individuals who maintain viral suppression after antiretroviral therapy (ART) during acute HIV-1 infection (AHI), according to a Thai study presented at the virtual Conference on Retroviruses and Opportunistic Infections (CROI) 2021.

ART initiation improves long-term depression symptoms in acute HIV

19 Mar 2021

Dolutegravir-lamivudine shows durable efficacy for HIV across patient subgroups

19 Mar 2021 by

Treatment-naïve individuals with HIV continued to benefit from the dolutegravir-lamivudine regimen for nearly 3 years regardless of baseline disease characteristics and demographics, as shown by its noninferiority to dolutegravir plus tenofovir and emtricitabine observed in the subgroup analyses of the GEMINI trials presented at CROI 2021.

Dolutegravir-lamivudine shows durable efficacy for HIV across patient subgroups

19 Mar 2021

People with HIV at high risk of CVD

19 Mar 2021 by

Even without a history of dyslipidaemia, hypertension, or diabetes, people with HIV (PWH) suffer from a nearly 30-percent higher risk of cardiovascular disease (CVD), according to a study presented at the 2021 Conference on Retroviruses and Opportunistic Infections (CROI 2021).

People with HIV at high risk of CVD

19 Mar 2021

Novel TB regimen shortens treatment time for HIV-infected patients

18 Mar 2021 by

A 4-month regimen containing the combination of rifapentine (RPT) and moxifloxacin (MOX) can effectively treat tuberculosis (TB) in HIV-positive patients, performing just as well as the 6-month standard of care, according to a subgroup analysis of the landmark phase III S31/A5349 trial.

Novel TB regimen shortens treatment time for HIV-infected patients

18 Mar 2021

Sex modifies link between inflammation, vascular events in ART-treated HIV

18 Mar 2021 by

Sex appears to have a strong influence on many discrete pathways of inflammation that independently predict cardiovascular disease (CVD) and venous thromboembolism (VTE) events in patients with HIV on antiretroviral therapy (ART), according to a study presented at the Conference on Retroviruses and Opportunistic Infections 2021.

Sex modifies link between inflammation, vascular events in ART-treated HIV

18 Mar 2021